AOXG: AI 评分 49/100 — AI 分析 (4月 2026)

Aoxing Pharmaceutical Company, Inc. focuses on the research, development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products in China. The company's key products include pain relief capsules, herbal supplements, and synthetic narcotic analgesics.

Key Facts: AI Score: 49/100 Sector: Healthcare

公司概况

概要：

Aoxing Pharmaceutical Company, Inc. is a specialty pharmaceutical company based in China, focusing on narcotic, pain-management, and addiction treatment products, including both herbal and synthetic drugs. With a negative P/E ratio and high gross margin, the company navigates a competitive landscape while developing new pain and addiction treatments.

AOXG是做什么的？

Aoxing Pharmaceutical Company, Inc., headquartered in Shijiazhuang, China, is a specialty pharmaceutical company dedicated to the research, development, manufacture, and distribution of pharmaceutical products. The company primarily operates in the People's Republic of China, focusing on narcotic, pain-management, and addiction treatment medications. Aoxing’s product portfolio includes Zhongtong'an, a herbal capsule designed for oral and dental pain relief, and Yiqi Qiangshen Granule, an over-the-counter herbal supplement aimed at tonifying qi, empowering the body, and promoting blood circulation. Additionally, the company manufactures Tilidine hydrochloride, a synthetic narcotic analgesic tablet used for moderate to severe pain relief. Further expanding their offerings, Aoxing has several products in development, including Oxycodone and Acetaminophen tablets and capsules, which have completed clinical trials for treating acute and chronic pain. They are also developing Buprenorphine/Naloxone, a sublingual tablet for opioid dependence treatment, which has completed Phase II clinical trials, and Tilidine/Naloxone, a compound capsule in Phase II clinical trials for acute and chronic pain management. Originally known as China Aoxing Pharmaceutical Company, Inc., the company rebranded to Aoxing Pharmaceutical Company, Inc. in March 2010, solidifying its commitment to advancing pharmaceutical solutions.

AOXG的投资论点是什么？

Aoxing Pharmaceutical Company, Inc. presents a high-risk, high-reward investment profile. The company's focus on the Chinese market for pain management and addiction treatment offers potential growth, especially with its pipeline of drugs like Oxycodone/Acetaminophen and Buprenorphine/Naloxone. However, the company's negative P/E ratio of -183.91 and a negative profit margin of -79.5% raise concerns about its financial stability. Successful navigation of clinical trials and regulatory approvals for its pipeline drugs are key catalysts. Investors should closely monitor the company's progress in these areas, as well as its ability to improve profitability and manage its high beta of -59.16.

AOXG在哪个行业运营？

Aoxing Pharmaceutical Company, Inc. operates within the specialty and generic drug manufacturing industry, a sector characterized by intense competition and stringent regulatory oversight. The Chinese pharmaceutical market is experiencing rapid growth, driven by an aging population and increasing healthcare spending. However, domestic companies face challenges from international players and evolving regulatory standards. Aoxing's focus on pain management and addiction treatment positions it in a niche market with specific needs, but also heightened regulatory scrutiny. Competitors like AREVF and CWWBF also operate in this space.

Drug Manufacturers - Specialty & Generic

Healthcare

AOXG有哪些增长机遇？

Expansion of Product Portfolio: Aoxing's pipeline of drugs in development, including Oxycodone/Acetaminophen and Buprenorphine/Naloxone, represents a significant growth opportunity. Successful completion of clinical trials and regulatory approvals could lead to new revenue streams and market share gains. The market for pain management and addiction treatment is substantial, with the global market estimated to reach billions of dollars in the coming years. Timeline: 2-5 years for regulatory approvals.
Geographic Expansion within China: While Aoxing primarily operates in China, there is potential to expand its geographic reach within the country. Targeting specific regions with high demand for pain management and addiction treatment products could drive revenue growth. This expansion could involve establishing new distribution channels and partnerships. Timeline: 1-3 years.
Strategic Partnerships and Acquisitions: Aoxing could pursue strategic partnerships or acquisitions to expand its product portfolio, geographic reach, or technological capabilities. Collaborating with other pharmaceutical companies or research institutions could accelerate the development and commercialization of new drugs. Timeline: Ongoing.
Increased Investment in Research and Development: Aoxing could increase its investment in research and development to discover and develop novel drugs for pain management and addiction treatment. This could involve conducting preclinical and clinical studies, as well as collaborating with academic institutions and research organizations. Timeline: Long-term, 5+ years.
Leveraging Government Support for Domestic Pharmaceutical Companies: The Chinese government is actively supporting the growth of domestic pharmaceutical companies through various policies and initiatives. Aoxing can leverage these policies to access funding, streamline regulatory approvals, and gain a competitive advantage. Timeline: Ongoing.

Market Cap of $0.00B indicates a micro-cap company with limited resources and higher volatility.
P/E Ratio of -183.91 reflects the company's current unprofitability, requiring careful evaluation of future earnings potential.
Gross Margin of 88.1% suggests strong pricing power on existing products, but this needs to translate into overall profitability.
Beta of -59.16 indicates an inverse correlation with the market, which is unusual and may be due to the stock's illiquidity or unique business model.
Focus on narcotic, pain-management, and addiction treatment pharmaceutical products in China, a market with significant unmet needs and growth potential.

AOXG提供哪些产品和服务？

Researches and develops pharmaceutical products focused on pain management, addiction treatment, and related areas.
Manufactures narcotic and non-narcotic pain relief medications.
Produces herbal extraction products for pain relief and general health improvement.
Distributes its pharmaceutical products primarily within the People's Republic of China.
Conducts clinical trials for new drug candidates, including treatments for opioid dependence.
Markets both prescription and over-the-counter (OTC) medications.

AOXG如何赚钱？

Develops and manufactures pharmaceutical products.
Sells prescription and OTC medications through distributors and directly to healthcare providers.
Generates revenue from the sale of its proprietary drug formulations.
Invests in research and development to create new products and improve existing ones.

Hospitals and clinics throughout China.
Pharmacies and drug stores.
Patients seeking pain relief and addiction treatment.
Healthcare providers prescribing medications.

Proprietary drug formulations and intellectual property.
Established distribution network within China.
Expertise in developing and manufacturing narcotic and pain-relief medications.
Regulatory approvals for its existing products.

什么因素可能推动AOXG股价上涨？

Upcoming: Regulatory approval and commercialization of Oxycodone and Acetaminophen tablets and capsules for pain management.
Upcoming: Positive results from Phase III clinical trials for Buprenorphine/Naloxone in treating opioid dependence.
Ongoing: Expansion of distribution network within China to reach more patients.
Ongoing: Increased government support for domestic pharmaceutical companies in China.
Ongoing: Growing demand for pain management and addiction treatment products in China.

AOXG的主要风险是什么？

Potential: Failure to obtain regulatory approvals for pipeline drugs.
Potential: Intense competition from established pharmaceutical companies.
Ongoing: Pricing pressures from generic drug manufacturers.
Ongoing: Dependence on the Chinese market and regulatory environment.
Potential: Product liability claims and lawsuits.

AOXG的核心优势是什么？

Specialized focus on pain management and addiction treatment.
Established manufacturing capabilities in China.
Pipeline of drugs in development.
Existing distribution network within China.

AOXG的劣势是什么？

Negative profitability and high debt levels.
Reliance on a single geographic market (China).
Limited financial resources for R&D and marketing.
OTC Other tier indicates higher risk.

AOXG有哪些机遇？

Expanding into new geographic markets.
Developing new drug formulations and delivery methods.
Partnering with other pharmaceutical companies.
Leveraging government support for domestic pharmaceutical companies.

AOXG面临哪些威胁？

Intense competition from established pharmaceutical companies.
Stringent regulatory requirements.
Pricing pressures from generic drug manufacturers.
Potential product liability claims.

AOXG的竞争对手是谁？

Ares Acquisition Corporation — Focuses on acquisitions rather than direct pharmaceutical competition. — (AREVF)
Cannaworld Brands Inc — Operates in the cannabis industry, a different segment of healthcare. — (CWWBF)
Firefinch Ltd — Primarily involved in mining operations, unrelated to pharmaceuticals. — (FFNTF)
Hempacco Co Inc — Focuses on hemp-based products, a different market segment. — (HMPQ)
NeuroBo Pharmaceuticals Inc — Develops and commercializes novel, disease-modifying therapies for neurodegenerative diseases. — (NBIO)

Key Metrics

MoonshotScore: 49/100

Company Profile

CEO: Zhenjiang Yue
Headquarters: Shijiazhuang, CN
Employees: 346
Founded: 2005

AI Insight

AI analysis pending for AOXG

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Aoxing Pharmaceutical Company, Inc. do?

Aoxing Pharmaceutical Company, Inc. is a specialty pharmaceutical company focused on the research, development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products, primarily in China. Its key products include Zhongtong'an capsules for oral pain, Yiqi Qiangshen Granule for general health, and Tilidine hydrochloride tablets for acute and chronic pain. The company is also developing new treatments for opioid dependence and pain management.

What do analysts say about AOXG stock?

As of 2026-03-17, there is no readily available analyst coverage or consensus for Aoxing Pharmaceutical Company, Inc. due to its OTC Other listing and limited financial disclosure. The company's negative P/E ratio and lack of profitability make valuation challenging. Investors should conduct thorough due diligence and assess the company's growth potential and risk factors independently. The stock's high beta suggests significant volatility.

What are the main risks for AOXG?

Aoxing Pharmaceutical Company, Inc. faces several key risks, including regulatory hurdles in China, intense competition from both domestic and international pharmaceutical companies, and the potential for product liability claims. The company's financial instability, as indicated by its negative P/E ratio and profit margin, also poses a significant risk. Additionally, its OTC Other listing implies limited transparency and liquidity, increasing the risk of price manipulation and delisting.